Immunoglobulin G4 (227-Proline), Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Psb103 .Gamma.4-Chain), Disulfide With Human Monoclonal Psb103 .Kappa.-Chain, Dimer
Non-Small Cell Lung Carcinoma
Explore 1,128 assets in Non-Small Cell Lung Carcinoma →Floatz Rating
B60/100
Confidence
Indicative
Sponsor
Tang-Du Hospital
Modality
monoclonal_antibody
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
58Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07538193CT.gov Iparomlimab and Tuvonralimab Plus Chemotherapy Before Surgery for Stage III Lung Cancer | — | Not Yet Recruiting | — | — | — |
NCT07453394CT.gov QLS5132 Combination Therapy in Advanced Solid Tumors | — | Not Yet Recruiting | — | — | — |
NCT07452003CT.gov An Exploratory Study of QL1706 Plus Chemotherapy in Perioperative NSCLC | — | Recruiting | — | — | — |
NCT07103395CT.gov A Study Evaluating Neoadjuvant Chemotherapy, Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade in Patients With Locally Advanced Non-Small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT07200947CT.gov A Phase II Study of QL1706 and Platinum-Based Chemotherapy in Patients With SMARCA4-Deficient, Locally Advanced or Metastatic Non-Small Cell Lung Cancer. | — | Not Yet Recruiting | — | — | — |
NCT07330596CT.gov QL1706 Combined With Chemotherapy in the Treatment of Immune-mediated NSCLC | — | Recruiting | — | — | — |
NCT07082179CT.gov A Prospective Phase II Clinical Study of Immunotherapy Combined With Chemotherapy for Stage III Unresectable Non-small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT07134413CT.gov QL1706/Bevacizumab ± Chemotherapy in Post-ICI Non-Squamous NSCLC | — | Not Yet Recruiting | — | — | — |
NCT07129161CT.gov Iparomlimab and Tuvonralimab Combined With 2 or 4 Cycles of Chemotherapy as Neoadjuvant Therapy for Resectable NSCLC | — | Not Yet Recruiting | — | — | — |
NCT06897046CT.gov Perioperative Study of Iparomlimab and Tuvonralimab in Resectable NSCLC | — | Recruiting | — | — | — |
Show 2 more trialsShow fewer
NCT05487391CT.gov A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection. | — | Recruiting | — | — | — |
NCT05329025CT.gov A Study of QL1706 Combined With Chemotherapy in Advanced Non-small Cell Lung Cancer | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Non-Small Cell Lung Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Immunoglobulin G4 (227-Proline), Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Psb103 .Gamma.4-Chain), Disulfide With Human Monoclonal Psb103 .Kappa.-Chain, Dimer (this asset) | Tang-Du Hospital | P3 | B · 60 |
| Necitumumab | Jonsson Comprehensive Cancer Center | P3 | BBB |
| Glumetinib | Shanghai JMT-Bio Inc. | P3 | BBB |
| Veliparib | AbbVie | P3 | BBB |
| d-0316 | Betta Pharmaceuticals Co., Ltd. | P2/3 | BBB |
| Icotinib | The First Affiliated Hospital of Guangzhou Medical University | P4 | BBB |
| Zoledronate | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | P4 | BBB |
| Onartuzumab | Hoffmann-La Roche | P3 | BBB |
| Avitinib | Hangzhou ACEA Pharmaceutical Research Co., Ltd. | P3 | BBB |
+42 more in the Non-Small Cell Lung Carcinoma cohort
Other indications for Immunoglobulin G4 (227-Proline), Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Psb103 .Gamma.4-Chain), Disulfide With Human Monoclonal Psb103 .Kappa.-Chain, Dimer
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Colorectal Cancer | — | P2 | CCC · 53 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Immunoglobulin G4 (227-Proline), Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Psb103 .Gamma.4-Chain), Disulfide With Human Monoclonal Psb103 .Kappa.-Chain, Dimer in Non-Small Cell Lung Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/immunoglobulin-g4-227-proline-anti-human-programmed-cell-death-protein-1-human-monoclonal-psb103-gamma4-chain-disulfide-with-human-monoclonal-psb103-kappa-chain-dimer-non-small-cell-lung-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →